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A widely accepted definition of resistance or intolerance to
hydroxyurea (HU) in patients with essential thrombocythemia
(ET) is lacking. An international working group (WG) was
convened to develop a consensus formulation of clinically
significant criteria for defining resistance/intolerance to HU
in ET. To this aim, an analytic hierarchy process (AHP), a
multiple-attribute decision-making technique, was used. The
steps consisted of selecting the candidate criteria for defining
resistance/intolerance; identifying the motivations that could
influence the preference of the WG for any individual criterion;
comparing the candidate criteria in a pair-wise manner; and
grading them according their ability to fulfill the motivations.
Every step in the model was derived by questionnaires or group
discussion. The WG proposed that the definition of resistance/
intolerance should require the fulfillment of at least one of the
following criteria: platelet count greater than 600 000/ll after
3 months of at least 2 g/day of HU (2.5 g/day in patients with
a body weight over 80 kg); platelet count greater than 400 000/ll
and WBC less than 2500/ll or Hb less than 10 g/dl at any dose
of HU; presence of leg ulcers or other unacceptable muco-
cutaneous manifestations at any dose of HU; HU-related fever.
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Introduction
Hydroxyurea (hydroxycarbamide, HU) is a non-alchilating
antineoplastic agent widely used for the treatment of myelo-
proliferative diseases, which interrupts the normal mechanism
of reduction of ribonucleotides and deoxyribonucleotides
through the inactivation of ribonucleotide reductase, limiting
DNA biosynthesis.1 HU may carry more or less severe side
effects: macrocytosis, neutropenia, leg and oral ulcers, cuta-
neous rash, skin dryness, nail pigmentation, cystitis, fever and
gastrointestinal symptoms.2,3 Moreover, a slight increase in skin
cancer has been reported in patients on HU.4 Finally, the
possible relationship between long-term therapy with HU and
leukemic transformation is still a matter of debate.3
HU is regarded as the first-choice platelet-lowering therapy in
most of patients with essential thrombocythemia (ET) according
to suggestions from experts in the field,5,6 from evidence-based
guidelines,7 and from the results of the MRC-PT1 study.8
However, up to 10% of the patients do not attain the desired
reduction of platelet number with the recommended dose of the
drug, thus exhibiting clinical resistance, whereas some will
develop unacceptable side effects, demonstrating clinical
intolerance.3,7–9 Despite these facts, there is neither widely
accepted definition of resistance nor of intolerance to HU, and
different authors have proposed different definitions that were
used either as a stopping rule in clinical trials or as management
recommendation in clinical practice.3,8–10
The absence of accepted criteria and the marked hetero-
geneity in the definitions of resistance/intolerance to HU in ET,
largely prevent any comparisons of the published reports. Thus,
a meaningful figure of the rate of resistance/intolerance to HU in
ET is lacking. A strict definition of resistance/intolerance to HU
is desirable for clinical studies aiming at assessing the efficacy of
platelet-lowering treatment of ET, particularly of second-line
therapies, like interferon and anagrelide. Such a definition is
also valuable for the clinical management of the patients,
particularly after the approval of anagrelide in European
countries from the agency for drug approval (EMEA) which
allowed the drug to be used as second-line therapy in ‘at-risk ET
patients who are intolerant to their current therapy or whose
elevated platelet counts are not reduced to an acceptable level
by their current therapy’.11
An international working group (WG) was formed with the
intention to produce, by a consensus process, a proposal for a
definition of resistance/intolerance to HU in patients receiving
the drug for ET as an initiative of the Chronic Myeloprolifera-
tive Disorders Working Party of the European Leukemia Net,
a network of excellence project funded by the European
Community. The WG was aware that providing criteria for
resistance/intolerance to HU required the selection of measure-
ments that were multifactorial in nature and whose metrics were
highly variable and difficult to define accurately. In an attempt
to consider all the factors that may affect the definition of
resistance/intolerance to HU, an analytic hierarchy process
(AHP), a multiple-criteria decision-making technique, was
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employed.12 Factors contributing to the choice of AHP include
its ability to simplify a complex problem in a concise easily
understood fashion and procedural simplicity. The final
purpose of the project was to identify rigorous, consistent and
feasible criteria applicable to future clinical trials and also to
routine practice.
Methods
The definition of resistance/intolerance to HU in patients with
ET was developed by a multistep process. A WG was constituted
in December 2005, composed of 15 experts in chronic
myeloproliferative disorders, and was chaired by a clinician
with expertise in clinical epidemiology (GB).
Framing the decision model
During the initial meeting, the WG agreed on the goal of the
project: to develop criteria for defining clinically significant
resistance and intolerance to HU in patients with ET treated with
this drug as platelet-lowering therapy. The WG agreed that
resistance and intolerance to HU are inter-related constructs, so
the goal was to produce a unified definition for them.
To create a decision model according to the AHP analysis,
and given the goal of the project, the motivations to be used for
evaluating how well the criteria produced would meet the goal
were discussed in detail during the initial meeting. It was agreed
that three motivations could influence the decision of preferring
one criterion to another for resistance/intolerance to HU,
namely: (a) avoid continuation of the drug when it has proven
to be ineffective in ‘high-risk’ disease; (b) avoid immediate
and long-term side effects of unnecessary continuation of the
drug; (c) avoid premature discontinuation of the drug whose
efficacy could be retarded. Figure 1 shows the way the decision
for selecting from the possible criteria could be framed as
an AHP model.
Selecting the criteria
We defined ‘criterion’ to be used in the definition of resistance/
intolerance to HU, any condition during the HU therapy
that, when occurring, can have a significant impact on the
management of patients with ET, and that could lead to
the discontinuation of the drug. We first aimed at selecting the
criteria in their conceptual terms, worded without any
numerical or quantitative attributes. To achieve this, a ques-
tionnaire was mailed to each member of the WG asking them to
propose candidate conceptual criteria that were further refined
in a Delphi process13 with a second questionnaire that asked
to rank the top choices among candidate criteria. All the
questionnaires were returned and the candidate conceptual
criteria were ranked according to their priority votes, with
the criteria that ranked highest and that received at least 80%
consensus to be included in the list, forming the core set of
conceptual criteria.
We then aimed at selecting the criteria in their operational
terms populating them with quantitative or numerical attributes.
To assess and select operational criteria, a third questionnaire
requested that the WG proposed candidate operational criteria
for each conceptual criterion. Subsequently, the WG ranked
these operational criteria and the highest-ranking ones (480%
consensus) formed the candidate operational criteria.
Pairwise comparison of operational criteria
The next step was to determine the importance of each
candidate operational criterion by pair wise comparison. Using
a bottom-up approach, the criteria were subjected to compar-
ison according to their ability to fulfill one of the three decision
motivations preliminarily selected for the decision according to
the preferences of the members of the WG. This part of the
process was exploited in a consensus meeting using the nominal
group technique.14 The comparisons were made between two
criteria at a time and each member of the WG was asked to
choose for that particular comparison which of the two he/she
considered more important for making the best decision. The
option achieving at least 80% consensus was then successively
ranked pair wise with the next in a progressive manner until
every pair of criteria has been evaluated. This process clarified
the expert’s judgments regarding which considerations are
pertinent and their relative importance, facilitating an open
discussion during the consensus process.
Results
The conceptual criteria
The WP listed eight conceptual criteria to be included as
candidates for the definition of resistance/intolerance to HU.
The four with the highest preference rate (480% consensus)
were: (a) not achieving the desired reduction of platelet count
after a critical time period at the maximum tolerated dose of
the drug; (b) not achieving the desired reduction of platelet
count but achieving a drug-dependent critical reduction of
white blood cells (WBC); (c) not achieving the desired reduction
of platelet count but achieving a drug-dependent critical
reduction of hemoglobin; (d) appearance of unacceptable
clinical side effects.
The candidate operational criteria
The WG listed 47 operational criteria to be included as
candidate criteria for the definition of resistance/intolerance to
HU. Twelve of them with the highest preference rate (480% of
consensus) are listed in Table 1. The first three criteria
operatively translated the motivations: ‘avoid continuation of
the drug when it has proven to be ineffective in high-risk
disease’, and ‘avoid premature discontinuation of the drug
whose efficacy could be retarded’, and represented the different
views among the experts about the number of platelet and time
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Figure 1 AHP model regarding the selection of criteria for resistance/
intolerance to HU in patients with essential ET. At the top is the goal of
the decision; at the bottom are the criteria to be decided; in the middle
are three motivations used for evaluating how well the options meet
the goal.
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for defining ineffectiveness of the therapy. The other criteria
operatively translated the motivation ‘avoid immediate and
long-term side effects of unnecessary continuation of the drug’.
Pairwise selection of the criteria
Using the pairwise comparisons, the 15 members of the WG
proposed that the definition of resistance/intolerance should
require the fulfillment of at least one of the criteria reported in
Table 2. The motivations for the decision varied among the
members of the WG, but most preferred to adopt a precau-
tionary principle that facilitated the conservative attitude
of avoiding side effect, both immediate and long term, of an
unnecessary use of the drug early after documentation of
ineffectiveness. This even though agreement was declared that
the long-term side effects of HU, like carcinogenesis, are not
clearly demonstrated.
Discussion
We report the results of a consensus process in achieving a
definition of resistance/intolerance to HU in patients with ET. In
the absence of scientific evidence of the risk of continuing
therapy after the documentation of a suboptimal response, the
WG was aware that searching for a definition of resistance/
intolerance to HU raised a complex decision issue, with the
pending drawbacks of the subjective and arbitrary nature of
the resulting criteria. To focus the problem, the panel of
experts used group techniques with the assumption that such
acknowledged experts have an implicit and comprehensive
mastery of scientific and practical information that would
yield the most appropriate definition. The value of such a
consensus approach to the definition of operational criteria
in medicine has been exploited in a high number of similar
processes reported in the literature.15,16 In this work, group
decision approach was based on AHP multiple criteria
decision-making process for overcoming many of the cognitive
and practical problems of decision problems that need to
select measurements that are multifactorial in nature, such
as the problem at hand. The AHP decision model was
adopted to help reducing a complex problem into small,
easily managed parts, ensuring that all important considera-
tions are taken in mind, and integrating multiple viewpoints
into the decision-making process in an explicit and unbiased
manner. The clinical effectiveness of decision-making
programs based on multicriteria methods has been deter-
mined, and data suggest that they can be implemented with
beneficial results.17–21
The results of this project suggest that resistance/intolerance to
HU can be defined with five critical events as specified in
Table 2. This definition is constructed of criteria widely used in
different definitions of the so-called resistance, ineffectiveness,
unresponsiveness or intolerance to HU previously reported in
the literature,3,8–10 but not in this precise combination. The
performing characteristics of the resulting definition should
be interpreted acknowledging the uncertainty inherent both
to the consensus process and to the panelists’ preferences
and attitudes. The former depends on the size of the expert
panel and the effectiveness of the decision model; the latter
reflects the absence of scientific evidence upon which to base
the definition.
The treatment of ET is problematic, and few evidence-based
directives can be given. The WG deliberately did not address
treatment guidelines but focused instead upon the important
issue of when to consider switching from therapy with HU to
that with other molecules. This will guide clinicians in when to
use drugs such as anagrelide that are licensed by the EMEA only
after resistance or intolerance to first-line therapy has been
documented. Moreover, these results may be adopted in
protocols of clinical trials in ET as stopping rule of the first-
line therapy with HU or inclusion criteria of second-line therapy
after HU.
In conclusion, the WG proposes the use of the presented
definition of resistance/intolerance to HU in ET patients, which
was developed using a strict AHP-based consensus process and
offers a definition to be adopted for clinical use, especially for
scientific trials.
Table 1 Candidate operational criteria for the definition of resistance/intolerance to HU in ET patients
Platelet count4600 000/ml after 3 months of at least 2.5 g/day of HU
Platelet count4600 000/ml after 3 months of at least 2 g/day of HU
Platelet count41 000 000/ml after 2 months of at least 2.5 g/day of HU
WBCo3000/ml and platelet count4600 000/ml after 3 months of at least 2 g/day of HU
WBCo2000/ml and platelet count4600 000/ml after 3 months of at least 2 g/day of HU
Hbo8 g/dl and a platelet count4600 000/ml after 3 months of at least 2 g/day of HU
Hbo10 g/dl and a platelet count4600 000/ml after 3 months of at least 2 g/day of HU
Hbo10 g/dl and a platelet count4500 000/ml after 3 months of at least 2 g/day of HU
Mucocutaneous manifestations unacceptable to the patient at any dose of HU
Oral or leg ulcers at any dose of HU
HU-related fever on treatment with HU at any dose
Symptomatic muco-cutaneous alterations at any dose of HU
Abbreviations: ET, essential thrombocythemia; HU, hydroxyurea.
Table 2 Definition of resistance/intolerance to HU in patients with ET
Platelet counto600 000/ml after 3 months of at least 2 g/day of HU (2.5 g/day in patients with a body weight480 kg)
Platelet counto400 000/ml and WBC less than 2500/ml at any dose of HU
Platelet counto400 000/ml and Hb less than10 g/dl at any dose of HU
Presence of leg ulcers or other unacceptable muco-cutaneous manifestations at any dose of HU
HU-related fever
Abbreviations: ET, essential thrombocythemia; HU, hydroxyurea; WBC, white blood cells.
Clinical resistance/intolerance to HU in ET
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